Roivant Sciences financials
$36.50−1.30%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 | FY24 Mar 31 | FY23 Mar 31 | FY22 Mar 31 |
|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M |
| Gross profit | $8.3M | $29.1M | $32.7M | $31.5M | $46.3M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 83.8% |
| Operating income | -$515.1M | -$1.11B | -$851.4M | -$906.8M | -$1.35B |
| Net income | -$299.8M | -$172.0M | $4.35B | -$1.01B | -$845.3M |
| Net margin | −3629.2% | −592.0% | 13294.2% | −3200.2% | −1528.9% |
| Diluted EPS | $-0.54 | $-0.24 | $5.23 | $-1.42 | $-1.26 |
| EBITDA | -$1.28B | -$1.10B | -$829.3M | -$887.9M | -$1.34B |
| Operating cash flow | -$750.3M | -$839.5M | -$765.3M | -$843.4M | -$677.7M |
| Free cash flow | -$758.6M | -$844.0M | -$766.6M | -$856.1M | -$695.2M |
| Diluted shares | 693.9M | 725.4M | 831.0M | 712.8M | 669.8M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $1.42B | $2.72B | $6.49B | $1.68B | $2.06B |
| Short-term investments | $2.87B | $2.17B | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $416.2M | $254.9M |
| Total assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B |
| Total liabilities | $416.3M | $249.7M | $774.0M | $782.0M | $523.7M |
| Shareholders' equity | $5.29B | $5.19B | $6.45B | $1.61B | $2.04B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology